| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6069585 | Journal of the American Academy of Dermatology | 2016 | 9 Pages |
Abstract
Doxycycline did not reduce the incidence of erlotinib-induced folliculitis, but significantly reduced its severity.
Keywords
EGFRNCICTCAEQOLECoGQuality of lifePFsTEAEErlotinibConsolidated Standards of Reporting Trialsprogression-free survivaloverall survivaldoxycyclinerashNon-small-cell lung cancerNSCLCDose intensityeastern cooperative oncology groupadverse eventtreatment-emergent adverse eventconfidence intervalFolliculitisCommon Terminology Criteria for Adverse EventsNational Cancer InstituteCONSORTEpidermal growth factor receptor
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Gaël MD, PhD, Radj MD, Alain MD, PhD, Lionel MD, Pierre-Jean MD, Jean-Michel MD, Bruno MD, Ghislaine MD, Hakim MD, Caroline MD, PhD, Olivier MD, PhD, CYTAR investigators CYTAR investigators,